CONFIRM: a phase III randomised trial to evaluate the efficacy of nivolumab versus placebo in relapsed mesothelioma

Hanna, G., Griffiths, G., Kirkpatrick, E.V. et al. (11 more authors) (2018) CONFIRM: a phase III randomised trial to evaluate the efficacy of nivolumab versus placebo in relapsed mesothelioma. In: Lung Cancer. 16th Annual British Thoracic Oncology Group Conference 2018, 24-26 Jan 2018, Dublin. Elsevier , S84-S84.

Metadata

Authors/Creators:
  • Hanna, G.
  • Griffiths, G.
  • Kirkpatrick, E.V.
  • Cozens, K.
  • Kalevras, M.
  • Maishman, T.
  • Danson, S.
  • Lester, J.
  • Ottensmeier, C.
  • Steele, N.
  • Szlosarek, P.
  • Lord, J.
  • Nye, M.
  • Fennell, D.
Copyright, Publisher and Additional Information: © 2018 Elsevier.
Dates:
  • Published (online): 21 February 2018
  • Published: January 2018
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Sheffield Teaching Hospitals
Depositing User: Symplectic Sheffield
Date Deposited: 30 Aug 2018 10:39
Last Modified: 30 Aug 2018 10:39
Published Version: https://doi.org/10.1016/S0169-5002(18)30216-2
Status: Published
Publisher: Elsevier
Refereed: Yes
Identification Number: https://doi.org/10.1016/S0169-5002(18)30216-2
Related URLs:

Download not available

A full text copy of this item is not currently available from White Rose Research Online

Share / Export

Statistics